Remy Hauser

At EyeCare Partners, we are on a mission to reinvent eye care by creating a network of optometry and ophthalmology practices that bring together a wealth of expertise, resources and knowledge. While our partner practices have unique cultures, we present a united front through our shared best practices, clinical research and innovative solutions to vision health. We believe everyone deserves to see life with the best vision possible. With over 300 ophthalmologists and 700 optometrists nationwide, we are committed to making high-quality eye care easy, accessible and personalized. We are elevating eye care for everyone.

We are PCI Pharma Services. CDMO. Today’s Drug Development & Manufacturing, Advanced Drug Delivery & Drug Device Combination Products, Clinical Trial Services, and Commercial Packaging Technology. Inspired by tomorrow. We provide world-class solutions through intelligence, ingenuity and innovation, together, delivering life-changing therapies. Across 38 global sites and supported by more than 8,000 dedicated employees, we bring together leading technology and continued investment to deliver seamless solutions from development to commercialization, supporting our clients to improve the lives of patients worldwide.

At FairJourney Bio, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 19 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether youre in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare.

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with 50+ years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services. Sterling believes that while science can be complex, partnerships should be simple. That’s why they have redefined the CDMO experience, marked by transparency, collaboration and trust; a Partnership Development and Manufacturing Organisation (PDMO®). Sterling has six facilities across the UK, USA and Europe, employing 1,350+ people, including in Cramlington and Newcastle, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Find out more: www.sterlingpharmasolutions.com/sterling-facilities

Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies. Pharmathen is committed to its vision to improve people’s lives through innovation and access to affordable medicines. The company has one of the most extensive and advanced pipelines in the industry, with a focus on long acting injectables (LAI), sustained release and ophthalmic formulations. Pharmathen’s highly diversified portfolio consists of over 100 commercialized products, which are produced in its US FDA and EU-approved manufacturing facilities in Greece, serving 250 customers and accessed by patients in more than 90 countries worldwide. Pharmathen is constantly strengthening its portfolio with innovative technologies and Long-Acting Therapeutic Technologies (LATTs) and has developed three fully certified technological platforms to achieve this. As a result, Pharmathen can provide a wide range of therapies which aim to improve treatment compliance for patients and support product Life Cycle Management (LCM) opportunities for customers. Pharmathen maintains a strong presence in all major markets and collaborates with the most significant organizations in the global pharmaceutical market, supported by a broad partner network in more than 90 countries worldwide. The company ranks among the top 50 pharmaceutical research companies in Europe and is one of the largest private sector investors in research and development in Greece. Pharmathen proudly employs more than 1,600 people from over 28 different nationalities, with 54% of its total workforce and 66% of its Research Operations Team being female. The companys enduring success is attributed to a passion for creativity, strong ethics, and the dedication of its people, who share a commitment to the companys vision of making a difference in people’s lives.

At EyeCare Partners, we are on a mission to reinvent eye care by creating a network of optometry and ophthalmology practices that bring together a wealth of expertise, resources and knowledge. While our partner practices have unique cultures, we present a united front through our shared best practices, clinical research and innovative solutions to vision health. We believe everyone deserves to see life with the best vision possible. With over 300 ophthalmologists and 700 optometrists nationwide, we are committed to making high-quality eye care easy, accessible and personalized. We are elevating eye care for everyone.

FR// Créé en 1967, accrédité selon la norme NF ISO 15189 depuis 1999, CERBA est le leader européen de la biologie médicale spécialisée. Concentrant plus de 40 spécialités médicales et employant plus de 600 personnes hautement qualifiées sur un site unique basé au nord-ouest de Paris, le laboratoire CERBA traite en moyenne 40 000 prélèvements par jour. Sa plateforme technologique de pointe lui permet de proposer aux laboratoires privés et hospitaliers sur plus de 50 pays un large panel d’examens de biologie spécialisée. CERBA développe constamment son potentiel technologique et humain et initie de nombreuses collaborations avec des structures publiques et privées pour être à la pointe de l’innovation. Depuis 1998, les équipes de CERBA ont participé à plus de 500 publications scientifiques. CERBA est par ailleurs le membre fondateur du groupe CERBA HEALTHCARE EN// Created in 1967 and accredited in compliance with the NF ISO 15189 standard since 1999, CERBA is the European leader in specialized clinical pathology. Integrating more than 40 medical specialties and employing over 600 highly qualified staff on a single site located to the north-west of Paris, on average CERBA handles some 40,000 dossiers daily. With a state-of-the-art technological platform, it is able to offer private and hospital laboratories in over 50 countries a wide range of specialized clinical pathology tests. CERBA ceaselessly works to develop its technological and human potential and has launched numerous collaborative projects with both public and private establishments to ensure it always remains on the leading-edge of innovation. Since 1998, CERBA's pathologists have contributed to over 500 scientific publications. CERBA is also a founder member of the CERBA HEALTHCARE group.